Chronic obstructive pulmonary disease (COPD) occurs in approximately 6.4% of the American population, and deaths from the disease continue to rise. Due to the progressive nature of COPD, a significant number of diagnosed individuals will be admitted to a long-term care facility during the course of the disease. Reports such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) report, which was extensively revised in 2017, continue to provide guidance regarding optimal diagnostic and treatment algorithms for COPD, while new and emerging therapies and devices look to provide a more personalized therapeutic approach. The integration of these recommendations and therapeutic approaches have the potential to benefit patients with COPD when placed into current management paradigms. Within this educational activity, a panel of experts in the field will assess the physical and psychosocial impact of COPD in patients in long-term care facilities, provide guidance for the incorporation of revised GOLD guidelines for the improvement of patient outcomes, as well as evaluate new advances in therapy and delivery devices for enhanced efficacy, patient adherence, and satisfaction.